• Users Online: 185
  • Print this page
  • Email this page


 
 Table of Contents  
LETTER TO EDITOR
Year : 2019  |  Volume : 2  |  Issue : 4  |  Page : 182

Response to “Platelet-rich plasma procedures and the responsible discontinuation of antithrombotic therapy” and “platelet-rich plasma protocols can potentiate vascular emboli: Establishing risks and benefits to the patient before performing the procedure”


H. Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX, USA

Date of Submission25-Nov-2019
Date of Acceptance25-Nov-2019
Date of Web Publication13-Dec-2019

Correspondence Address:
Dr. Prathap Jayaram
H. Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, Houston, TX
USA
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/jisprm.jisprm_62_19

Rights and Permissions

How to cite this article:
Jayaram P. Response to “Platelet-rich plasma procedures and the responsible discontinuation of antithrombotic therapy” and “platelet-rich plasma protocols can potentiate vascular emboli: Establishing risks and benefits to the patient before performing the procedure”. J Int Soc Phys Rehabil Med 2019;2:182

How to cite this URL:
Jayaram P. Response to “Platelet-rich plasma procedures and the responsible discontinuation of antithrombotic therapy” and “platelet-rich plasma protocols can potentiate vascular emboli: Establishing risks and benefits to the patient before performing the procedure”. J Int Soc Phys Rehabil Med [serial online] 2019 [cited 2020 May 30];2:182. Available from: http://www.jisprm.org/text.asp?2019/2/4/182/272898



Sir,

Dr. Anitua et al.'s and Dr. Tan et al.'s comments are appreciated. The authors did not treat this patient for his elbow. We became aware of the problem in taking his history for another problem. We were believed that the issue of sequelae from aspirin cessation was important to report. The patient spoke with his cardiologist about the proposed platelet-rich plasma (PRP) treatment but did not raise the issue of aspirin cessation. He then reported to the treating physiatrist that he received approval for PRP treatment. No further discussion or inquiry was done, and the treatment was delivered as described.

The authors' goal in presenting this case report is to highlight the parameters of anticoagulation effects on PRP efficacy. Subsequently, in our recent study in the AJSM 2019 “Effects of Aspirin on Growth Factor Release from Freshly Isolated Leukocyte-Rich Platelet-Rich Plasma in Healthy Men: A Prospective Fixed-Sequence Controlled Laboratory Study,” we demonstrated these effects. This case highlights that while the safety of biological strategies such as PRP have shown excellent safety profile, off-target effects of medications and cessation can lead to unintended consequences. We agree with the responses in that more standardized protocols are needed to optimize PRP efficacy and unintended consequences.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.






 

Top
 
 
  Search
 
Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
Access Statistics
Email Alert *
Add to My List *
* Registration required (free)

 
  In this article

 Article Access Statistics
    Viewed272    
    Printed42    
    Emailed0    
    PDF Downloaded42    
    Comments [Add]    

Recommend this journal


[TAG2]
[TAG3]
[TAG4]